EXTON, Pa., Jan. 25 /PRNewswire-FirstCall/ -- Kensey Nash Corporation will present at the Brean Murray, Carret Small Cap Institutional Investor Conference at The Grand Hyatt New York Hotel in New York, New York on Wednesday, February 1, 2006.
Joseph W. Kaufmann, Kensey Nash’s President & CEO, will deliver the Company’s presentation, beginning at approximately 1:30 p.m. (EST). The presentation materials will be available on the company’s website (http://www.kenseynash.com) beginning at 1:30 p.m. (EST) on Wednesday, February 1, 2006 and will remain on the website for approximately two weeks. Wall Street Webcasting will also have the presentation available at http://www.wsw.com/webcast/bmry2/knsy/ beginning at 1:30 p.m. (EST) on February 1, 2006.
About Kensey Nash Corporation. Kensey Nash Corporation is a leading developer and manufacturer of medical devices with applications in the cardiology, orthopaedics, spine, drug and biologics delivery, periodontal/dental, surgical and wound care markets. The Company’s endovascular product platform currently includes the TriActiv(R) System, a novel embolic protection system, which is approved for sale in the U.S., as well as the TriActiv(R) FX(TM) System, the second generation of the TriActiv(R) System, which is approved for sale in the European Union. In addition, 510(k) applications are pending on the Company’s TriActiv(R) FX(TM) and its ThromCat(R) and QuickCat(R) thrombus removal products for approval to sell in the U.S. The Company was a pioneer in the field of absorbable biomaterials-based products and in arterial puncture closure, as the inventor and developer of the Angio-Seal(TM) Vascular Closure Device, which is licensed to St. Jude Medical, Inc.
Statements made during the presentation that are not historical facts are forward-looking statements that are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. The Company cautions that a number of important factors could cause the Company’s actual results to differ materially from those in the forward-looking statements. For a more detailed discussion of these and other factors, please see the Company’s SEC filings. Results of operations in any past period should not be considered indicative of the results to be expected for future periods. Fluctuations in operating results may also result in fluctuations in the price of the Common stock.
Kensey Nash Corporation
CONTACT: Joseph W. Kaufmann, President and Chief Executive Officer ofKensey Nash Corporation, +1-484-713-2100
Web site: http://www.kenseynash.com//
